Inhaled Drug Reduced Lung Disease Recurrence
A new treatment for Mycobacterium avium complex lung disease helped adults improve respiratory symptoms.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Should the FDA prioritize fast-track approval for new drugs treating chronic respiratory infections?
In the phase 3b ENCORE trial, adults with newly diagnosed Mycobacterium avium complex lung disease saw improved respiratory symptoms when adding a daily inhaled drug to their standard antibiotic regimen. The FDA has now granted Priority Review to this treatment, which could offer a new option for patients facing frequent disease recurrence.
Why it matters
Treatment failure and disease recurrence are common complications of standard multidrug therapy for this condition. This development aims to provide a more effective way to achieve durable culture conversion, potentially reducing the long-term impact on lung health.
In the phase 3b ENCORE trial, antibiotic-naive adults received standard multidrug therapy plus 590 mg of amikacin liposome inhalation suspension or a placebo over 12 months. Results showed significant improvements in symptoms and durable culture conversion compared to the empty-liposome group.
The players
Insmed
A biopharmaceutical company focused on developing therapies for serious, rare respiratory diseases and inflammatory conditions.
FDA
The federal agency responsible for evaluating the safety and efficacy of new drug applications in the United States.
The details
The treatment works by delivering amikacin directly to the lungs via liposomal suspension to combat bacterial infections. Researchers used whole genome sequencing to distinguish between a relapse of the original bacterial strain and a genetically distinct reinfection. This precise tracking helped confirm that the inhaled suspension more effectively cleared the underlying Mycobacterium avium complex infection compared to standard therapy alone.
Timeline
September 5-9, 2026: ENCORE trial data presented at the ERS Congress.
September 28, 2026: The FDA granted Priority Review to the supplemental new drug application.
January 28, 2027: PDUFA target action date for the FDA decision.
Health Landscape
This development represents a departure from relying solely on oral multidrug therapy, which frequently leads to treatment failure in approximately 40% of cases. The findings from the ENCORE trial offer a targeted approach that aims to improve bacterial clearance and symptom management.
If you are currently managing Mycobacterium avium complex lung disease, discuss these trial results with your pulmonologist to understand how they might impact future treatment options. It is important to wait for the official FDA regulatory outcome before considering any changes to your therapy.
The takeaway
This trial demonstrates that targeted inhaled therapy may significantly improve outcomes for patients battling recurrent lung infections. Patients should continue their current prescribed regimen and ask their physician about upcoming treatment options that focus on achieving durable bacterial clearance.
What happens next
The FDA is scheduled to reach a final decision on the supplemental new drug application by January 28, 2027.
Further reading
For additional context on managing chronic airway conditions, visit our Asthma section.
Live Poll
Should the FDA prioritize fast-track approval for new drugs treating chronic respiratory infections?
